You are currently viewing a new version of our website. To view the old version click .

Most Cited

  • Review
  • Open Access
58 Citations
25,356 Views
184 Pages

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

  • Bradford L. Therrell,
  • Carmencita D. Padilla,
  • Gustavo J. C. Borrajo,
  • Issam Khneisser,
  • Peter C. J. I. Schielen,
  • Jennifer Knight-Madden,
  • Helen L. Malherbe and
  • Marika Kase

Newborn bloodspot screening (NBS) began in the early 1960s based on the work of Dr. Robert “Bob” Guthrie in Buffalo, NY, USA. His development of a screening test for phenylketonuria on blood absorbed onto a special filter paper and transp...

  • Review
  • Open Access
31 Citations
8,392 Views
15 Pages

Liquid Chromatography–Tandem Mass Spectrometry in Newborn Screening Laboratories

  • Michael H. Gelb,
  • Khaja Basheeruddin,
  • Alberto Burlina,
  • Hsiao-Jan Chen,
  • Yin-Hsiu Chien,
  • George Dizikes,
  • Christine Dorley,
  • Roberto Giugliani,
  • Amy Hietala and
  • Xinying Hong
  • + 16 authors

Tandem mass spectrometry (MS/MS) is the most universal platform currently available for the analysis of enzymatic activities and biomarkers in dried blood spots (DBS) for applications in newborn screening (NBS). Among the MS/MS applications in NBS, t...

  • Review
  • Open Access
27 Citations
8,220 Views
14 Pages

Current State and Innovations in Newborn Screening: Continuing to Do Good and Avoid Harm

  • Giancarlo la Marca,
  • Rachel. S. Carling,
  • Stuart. J. Moat,
  • Raquel Yahyaoui,
  • Enzo Ranieri,
  • James. R. Bonham and
  • Peter. C. J. I. Schielen

In 1963, Robert Guthrie’s pioneering work developing a bacterial inhibition assay to measure phenylalanine in dried blood spots, provided the means for whole-population screening to detect phenylketonuria in the USA. In the following decades, N...

  • Article
  • Open Access
23 Citations
4,850 Views
15 Pages

Australian Public Perspectives on Genomic Newborn Screening: Risks, Benefits, and Preferences for Implementation

  • Fiona Lynch,
  • Stephanie Best,
  • Clara Gaff,
  • Lilian Downie,
  • Alison D. Archibald,
  • Christopher Gyngell,
  • Ilias Goranitis,
  • Riccarda Peters,
  • Julian Savulescu and
  • Sebastian Lunke
  • + 2 authors

Recent dramatic reductions in the timeframe in which genomic sequencing can deliver results means its application in time-sensitive screening programs such as newborn screening (NBS) is becoming a reality. As genomic NBS (gNBS) programs are developed...

  • Review
  • Open Access
23 Citations
4,866 Views
17 Pages

Newborn Screening for Fabry Disease: Current Status of Knowledge

  • Vincenza Gragnaniello,
  • Alessandro P. Burlina,
  • Anna Commone,
  • Daniela Gueraldi,
  • Andrea Puma,
  • Elena Porcù,
  • Maria Stornaiuolo,
  • Chiara Cazzorla and
  • Alberto B. Burlina

Fabry disease is an X-linked progressive lysosomal disorder, due to α-galactosidase A deficiency. Patients with a classic phenotype usually present in childhood as a multisystemic disease. Patients presenting with the later onset subtypes have...

  • Article
  • Open Access
21 Citations
4,013 Views
14 Pages

Light and Shadows in Newborn Screening for Lysosomal Storage Disorders: Eight Years of Experience in Northeast Italy

  • Vincenza Gragnaniello,
  • Chiara Cazzorla,
  • Daniela Gueraldi,
  • Andrea Puma,
  • Christian Loro,
  • Elena Porcù,
  • Maria Stornaiuolo,
  • Paolo Miglioranza,
  • Leonardo Salviati and
  • Alessandro P. Burlina
  • + 1 author

In the last two decades, the development of high-throughput diagnostic methods and the availability of effective treatments have increased the interest in newborn screening for lysosomal storage disorders. However, long-term follow-up experience is n...

  • Review
  • Open Access
18 Citations
4,508 Views
8 Pages

Implementation of Newborn Screening for Conditions in the United States First Recommended during 2010–2018

  • Sikha Singh,
  • Jelili Ojodu,
  • Alex R. Kemper,
  • Wendy K. K. Lam and
  • Scott D. Grosse

The Recommended Uniform Screening Panel (RUSP) is the list of conditions recommended by the US Secretary of Health and Human Services for inclusion in state newborn screening (NBS). During 2010–2022, seven conditions were added to the RUSP: sev...

  • Opinion
  • Open Access
17 Citations
3,884 Views
16 Pages

Inborn errors of immunity (IEI) are a group of over 450 genetically distinct conditions associated with significant morbidity and mortality, for which early diagnosis and treatment improve outcomes. Newborn screening for severe combined immunodeficie...

  • Systematic Review
  • Open Access
17 Citations
5,646 Views
33 Pages

Systematic Review of Newborn Screening Programmes for Spinal Muscular Atrophy

  • Katy Cooper,
  • Gamze Nalbant,
  • Anthea Sutton,
  • Sue Harnan,
  • Praveen Thokala,
  • Jim Chilcott,
  • Alisdair McNeill and
  • Alice Bessey

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder causing the degeneration of motor neurons in the spinal cord. Recent studies suggest greater effectiveness of treatment in the presymptomatic stage. This systematic review synthesises...

  • Article
  • Open Access
15 Citations
3,541 Views
6 Pages

Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor–Tezacaftor–Ivacaftor

  • Payal Patel,
  • Jana Yeley,
  • Cynthia Brown,
  • Melissa Wesson,
  • Barbara G. Lesko,
  • James E. Slaven,
  • James F. Chmiel,
  • Raksha Jain and
  • Don B. Sanders

Most people with cystic fibrosis (CF) are diagnosed following abnormal newborn screening (NBS), which begins with measurement of immunoreactive trypsinogen (IRT) values. A case report found low concentrations of IRT in an infant with CF exposed to th...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Int. J. Neonatal Screen. - ISSN 2409-515XCreative Common CC BY license